Key facts
- EBAMed’s last known valuation is $105.6M (Jun 2025).
- It has raised $51.1M; the latest was Later Stage VC ($29.9M) in Jun 2025.
- Notable investors include MassChallenge, European Innovation Council, Venture Kick, CDP Venture Capital (Rome), European Union — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for EBAMed
- ·The full record, as it builds
Funding rounds
No funding rounds for EBAMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EBAMed
Developer of the next-generation radiation therapy technology designed to treat cardiac arrhythmias from outside the heart. The company's device utilizes proton therapy, capable of selectively treating the tissues responsible for heart arrhythmias, enabling patients to undergo a non-invasive treatment in a single outpatient session.
- Sector
- Healthcare
- HQ
- Geneva, Switzerland
- Founded
- 2018
- Employees
- 3
- Website
- eba-med.com/
- Ownership
- Privately Held (backing)
EBAMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EBAMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EBAMed in its N-PORT filings yet. We sweep new filings monthly.